These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15304522)

  • 1. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
    Polasek TM; Elliot DJ; Lewis BC; Miners JO
    J Pharmacol Exp Ther; 2004 Dec; 311(3):996-1007. PubMed ID: 15304522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.
    Polasek TM; Elliot DJ; Somogyi AA; Gillam EM; Lewis BC; Miners JO
    Br J Clin Pharmacol; 2006 May; 61(5):570-84. PubMed ID: 16669850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
    Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
    Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants.
    Murray M; Field SL
    Biochem Pharmacol; 1992 May; 43(10):2065-71. PubMed ID: 1599495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
    Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
    Filppula AM; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
    Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
    Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The xenobiotic inhibitor profile of cytochrome P4502C8.
    Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
    Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
    Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
    Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
    Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.
    Projean D; Baune B; Farinotti R; Flinois JP; Beaune P; Taburet AM; Ducharme J
    Drug Metab Dispos; 2003 Jun; 31(6):748-54. PubMed ID: 12756207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
    Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
    Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.
    Li XQ; Björkman A; Andersson TB; Ridderström M; Masimirembwa CM
    J Pharmacol Exp Ther; 2002 Feb; 300(2):399-407. PubMed ID: 11805197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
    Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
    Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
    Ernest CS; Hall SD; Jones DR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes.
    Yamazaki H; Shibata A; Suzuki M; Nakajima M; Shimada N; Guengerich FP; Yokoi T
    Drug Metab Dispos; 1999 Nov; 27(11):1260-6. PubMed ID: 10534310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.